LDN-212320 is primarily researched for its potential applications in neuroscience and mental health. It is being studied for its role as a selective antagonist of the kappa opioid receptor (KOR), which is implicated in mood regulation, stress response, and addiction. Researchers are exploring its use in treating conditions such as depression, anxiety, and substance abuse disorders, as modulating KOR activity may help alleviate symptoms associated with these conditions. Additionally, it is being investigated for its potential to reduce cravings and relapse in individuals struggling with addiction. Its application in preclinical studies has shown promise in improving mood-related behaviors and stress resilience, making it a candidate for future therapeutic development.